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Glutamate-mediated toxicity has been implicated in the neuro-
degeneration observed in Alzheimer’s disease. In particular,
glutamate transport dysfunction may increase susceptibility to
glutamate toxicity, thereby contributing to neuronal cell injury
and death. In this study, we examined the cellular localization of
the glial glutamate transporter excitatory amino acid trans-
porter 1 (EAAT1) in the cerebral cortex of control, Alzheimer’s
disease, and non-Alzheimer dementia cases. We found that
EAAT1 was strongly expressed in a subset of cortical pyramidal
neurons in dementia cases showing Alzheimer-type pathology.
In addition, tau (which is a marker of neurofibrillary pathology)
colocalized to those same pyramidal cells that expressed
EAAT1. These findings suggest that EAAT1 changes are related
to tau expression (and hence neurofibrillary tangle formation) in
dementia cases showing Alzheimer-type pathology. This study
implicates aberrant glutamate transporter expression as a
mechanism involved in neurodegeneration in Alzheimer’s
disease.
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A link between glutamate transporter dysfunction, increased ex-
tracellular glutamate levels, and onset of excitotoxic neuronal
damage has been established in animal models (Rothstein et al.,
1996; Rao et al., 2001) and in some human neurodegenerative
diseases, such as amyotrophic lateral sclerosis (Rothstein et al.,
1992, 1995; Lin et al., 1998). Altered glutamate transport has been
implicated in Alzheimer’s disease (AD), with biochemical studies
showing reduced numbers of high-affinity glutamate uptake sites
in AD in many cortical areas and a lower maximal D-[3H]aspartate
uptake rate (early studies by Cross et al., 1987; Cowburn et al.,
1988) (for review, see Scott et al., 1995). Different pharmacolog-
ical profiles of glutamate transporter sites have also been found in
a number of cortical regions in AD cases compared with controls
(Dodd et al., 1994).
A number of excitatory amino acid transporters (EAATs) have
now been isolated and characterized (for review, see Robinson,
1999). EAAT1 is primarily localized to glia in the cerebellum and
retina (Rothstein et al., 1994; Lehre et al., 1995); EAAT2 is
specifically located on astrocytes and is quantitatively dominant
in cortex (Arriza et al., 1994; Rothstein et al., 1994; Chaudhry et
al., 1995; Lehre et al., 1995); EAAT3 has a postsynaptic neuronal
localization that includes non-glutamatergic neurons (Rothstein
et al., 1994); EAAT4 is located in cerebellar Purkinje cells
(Dehnes et al., 1998); and EAAT5 is restricted to photoreceptors
in the retina (Pow and Barnett, 2000).
A significant reduction in EAAT2 protein expression levels has
been reported in the midfrontal cortex of AD cases, with no
changes observed for EAAT1 or EAAT3 (Li et al., 1997). A
separate study found that EAAT1 and EAAT2 expression and
protein levels were not correlated with AD in the cingulate and
inferior temporal gyri (Beckstrøm et al., 1999). In a transgenic
mouse model expressing the 695 amino acid form of the human
amyloid precursor protein with the London mutation (a mutation
which occurs in a small percentage of familial AD cases), a
reduction in EAAT1 and EAAT2 protein levels in the neocortex
was observed (Masliah et al., 2000). The previous AD study
(Beckstrøm et al., 1999) and the transgenic mouse study (Masliah
et al., 2000) reported light immunolabeling for EAAT1 in pyra-
midal cells in the cortex, as well as glial labeling.
Because neuronal cells are susceptible to the effects of gluta-
mate toxicity (Choi, 1992), we further explored this finding by
examining the cellular localization of EAAT1 in a range of
human dementia cases that showed variable pathology, compared
with human controls. One of the neuropathological features of
AD is the formation of neurofibrillary tangles (NFTs) within
neurons. NFTs contain paired helical filaments composed of the
microtubule-associated protein tau in a hyperphosphorylated
state (Goedert, 1993). Therefore, tau was used as a marker of
damaged neurons to determine whether changes in EAAT1 ex-
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pression could be connected to these cells and thus involved in the
process of cell injury. Because the previous studies had only
included areas susceptible to damage, we also studied an area that
is relatively spared from pathology (i.e., the motor cortex) to
determine whether any changes in EAAT1 expression were re-
stricted in their distribution and thus might account for the
regional specificity of AD neuropathology. In this study, we show
that the glial glutamate transporter EAAT1 is selectively ex-
pressed in degenerating neurons and dystrophic neurites in AD
cases, and that this altered expression is closely associated with
neurofibrillary pathology.
MATERIALS AND METHODS
Human tissue samples. Brain tissue was obtained at autopsy from a total
of 18 patients, including 13 cases diagnosed with dementia and 5 control
cases (Table 1). Autopsies were performed by authorized pathologists for
confirmation of diagnosis or other clinical imperative; informed consent
was obtained from the next of kin in all cases. The control cases did not
meet any criteria for a neurological disease either clinically or patholog-
ically. Of the 13 dementia cases, 5 were pathologically diagnosed as AD,
5 showed a combined Lewy body disease and Alzheimer-type pathology,
2 cases were diagnosed as pure Lewy body disease (showing no
Alzheimer-type pathology), and 1 case had a diagnosis of multi-infarct
dementia (with no Alzheimer-type changes).
Tissue was fixed for 20–24 hr by immersion in 4% buffered parafor-
maldehyde at 4°C (Pow, 1996), rinsed in 0.1 M PBS, pH 7.2, and stored in
0.1% buffered paraformaldehyde/sodium azide at 4°C until use. Samples
of the midtemporal gyrus and motor cortex (precentral gyrus) were
collected so that an area susceptible to pathological damage (temporal
cortex) could be compared with a relatively spared area (motor cortex).
“Susceptible” and “spared” areas taken from the same brains served as
internal controls, thus reducing confounders such as preterminal medi-
cation, agonal factors, and postmortem delay.
Immunocytochemistry. Vibratome sections (50 m) were immunola-
beled by a “free-floating” method optimized from standard techniques
(Pow, 1996). Four sections were sampled per area for each case. Sections
were pretreated in 1% H2O2 to remove endogenous peroxidase activity,
blocked in 0.5% bovine serum albumin/0.05% saponin/PBS, and incu-
bated with primary antibody (diluted in blocking solution). Well-
characterized polyclonal antibodies directed against EAAT1 that have
been raised in rabbits or guinea pigs against either an N-terminal se-
quence (Pow and Barnett, 1999) or a C-terminal sequence (human
sequence 504–519; KNRDVEMGNSVIEENE) by Dr. Pow were used.
However, for most of the study, rabbit antiserum to the N terminus was
used. The antibody for tau was a mouse monoclonal antibody obtained
commercially from Sigma (Sydney, Australia). Sections were incubated
with biotinylated secondary antibody, rinsed, and incubated with strepta-
vidin–biotin horseradish peroxidase (SAB–HRP) complex. After exten-
sive washing in PBS, detection of labeling was by incubation with diami-
nobenzidine (DAB; 0.2 mg/ml) in PBS and 0.001% H2O2.
To define the relationship between glutamate transporter expression
and pathological indices of AD, double-labeling studies were required. A
sequential double chromagen method for EAAT1 and tau was developed.
This method was chosen in preference to immunofluorescence methods
because autofluorescence of lipofuscin in human tissues (Dowson and
Harris, 1981) makes double-fluorescence immunolabeling studies ambig-
uous in their interpretation. After pretreatment with H2O2 and blocking,
sections were incubated with the two primary antibodies (against
EAAT1 and tau) simultaneously. Sections were then incubated with
species-specific secondary antibodies that recognized the two different
primary antibodies. An alkaline phosphatase-coupled anti-rabbit second-
ary antibody was used for the EAAT1 antibody, whereas an anti-mouse
biotinylated secondary antibody was used for tau. The sections were then
incubated with SAB–HRP complex (for completion of the avidin–biotin
complex method that was used for detection of tau; no tertiary amplifi-
cation step was required for the alkaline phosphatase substrate method
used for EAAT1).
After extensive washing in 0.1 M Tris buffer, pH 7.4, the alkaline
phosphatase-conjugated secondary antibody (that marks labeling for
EAAT1) was detected first using the red chromagen Fast Red. Sigma
FAST (Fast Red TR/Napthol AS-MIX Alkaline Phosphatase Substrate
Tablet Sets) was used as per the manufacturer’s instructions. Sections
were washed in PBS, followed by detection of the next secondary anti-
body using the avidin–biotin horseradish peroxidase technique with the
chromagen DAB in the presence of 0.001% H2O2 and nickel ions (0.02%
nickel ammonium sulfate). This gave rise to a black reaction product. By
documenting all red-stained cells before the second immunostaining step
through photography or with a camera lucida, it was possible to demon-
strate double labeling, even when labeling of the two chromogens was
associated with the same cells. For all immunocytochemical methods,
sections from susceptible and spared areas from control and dementia
brains were processed in batches to achieve consistent immunostaining
and to allow qualitative comparisons between cases.
Controls were performed to confirm that the secondary antibodies did
not bind to the inappropriate primary antibodies in the double-labeling
experiments. Exclusion of either the EAAT1 or the tau primary antibody





diagnosis Cause of death
1 71 19.5 M Normal Perioperative myocardial infarct
2 82 46.8 M Normal Cardiorespiratory arrest
3 57 33.7 F Normal NA
4 66 8.7 M Normal Multiple system atrophy
5 78 4.0 F Normal Myocardial infarct
6 80 24.0 F AD NA
7 87 35.5 F AD Bowel obstruction
8 70 9.5 F AD NA
9 84 24.0 M AD Renal failure with oliguria
10 61 14.8 F AD Chest infection
11 77 24.0 F LBD/AD NA
12 84 41.9 F LBD/AD Occult carcinoma, AD
13 88 25.5 F LBD/AD NA
14 80 13.5 F LBD/AD NA
15 83 38.8 M LBD Pneumonia
16 88 48.0 M LBD Left ventricular failure
17 75 24.0 F LBD/AD/PD NA
18 79 55.3 M Multi-infarct dementia Cerebrovascular accident
M, Male; F, female; LBD, Lewy body disease; PD, Parkinson’s disease; NA, not available.
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while treating the tissue with both secondary antibodies and processing
as above resulted in labeling only for EAAT1 or tau as appropriate.
Materials. The secondary antibodies and streptavidin–biotin horse-
radish peroxidase complex were obtained from Amersham Biosciences
(Sydney, Australia). All other chemicals were obtained from BDH
Chemicals (Kilsyth, Australia) or Sigma and were of analytical grade.
RESULTS
The cellular localization of EAAT1 and tau was examined by
immunocytochemical techniques. In the midtemporal cortex,
EAAT1 labeling (using the N-terminal antibody) occurred in a
distinct proportion of neuronal cells in all AD cases and cases
with combined AD and Lewy body disease pathology (i.e., 10 of
the 18 cases studied). This labeling was primarily in pyramidal
neurons in cortical layers III and IV (Fig. 1a). Dystrophic neurites
also labeled for EAAT1 in association with structures that ap-
peared to represent senile plaques in cases showing Alzheimer-
type pathology (Fig. 1b). Numerous immunolabeled cells were
observed in AD cases, with the numbers generally reflecting the
degree of neuropathology observed (Fig. 2a). The remaining
cases (i.e., the controls and dementia cases showing no
Alzheimer-type pathology) showed no or extremely rare
EAAT1-positive cells in the midtemporal cortex (Fig. 2b). Glial
staining of EAAT1 was not conspicuous in any case.
The motor cortex, which is generally an area that is relatively
free of pathological changes in AD, showed varied results. Mod-
est staining of pyramidal neurons for EAAT1 was observed in all
AD cases and one combined Lewy body disease/AD case (i.e., 6
of the 18 cases). Some cases had a few EAAT1-positive neuronal
cells, whereas other cases had numerous labeled cells. The re-
maining cases showed no EAAT1-positive cells in the motor
cortex. Labeling for EAAT1 and tau was not observed in the large
Betz cells of the motor cortex (data not shown). No glial staining
was conspicuous in any case.
EAAT1 labeling could be blocked by preincubation with both
10 g/ml and 100 g/ml peptide for the N-terminal antibody
raised in rabbit. The specificity of the results was examined using
additional antibodies for EAAT1. Similar aberrant expression of
EAAT1 was shown by both the C-terminal antibody raised in
rabbit (Fig. 3a) and the N-terminal antibody raised in guinea pig
(Fig. 3b).
We tested whether these changes could be related to a patho-
logical marker of AD by using a sequential double-
immunolabeling technique to determine the colocalization of
EAAT1 and tau. In all cases, tau colocalized with EAAT1 (i.e.,
every cell that stained for tau also stained for EAAT1). This
colocalization occurred in the neurons, in dystrophic neurites
(Figs. 1c,d, 2c,d), and in both cortical regions. However, we found
occasional EAAT1-positive cells that exhibited no tau labeling
(Fig. 4).
DISCUSSION
These data suggest that there is abnormal expression of EAAT1
under certain circumstances in human cortex. In cases showing
Alzheimer-type neuropathology, EAAT1 was expressed in neu-
rons, primarily a subset of pyramidal cells, and in dystrophic
neurites. This aberrant expression was closely associated with tau
deposition and hence neurofibrillary changes. The inclusion of
Figure 1. Colocalization of immunostaining for EAAT1 and tau anti-
bodies in neurons and dystrophic neurites. a, c, Labeling of a pyramidal
neuron (arrows) in the midtemporal cortex. a, Immunostaining with
EAAT1 antibodies. c, Subsequent double-immunostaining of the same
neuron with tau antibodies. b, d, Labeling of neurons and dystrophic
neurites (arrows) in the midtemporal cortex. b, Immunostaining with
EAAT1 antibodies. d, Subsequent double-immunostaining with tau anti-
bodies labels the same structures. Scale bars, 20 m.
Figure 2. Localization of EAAT1 and tau expression in pyramidal
neurons in control and AD cases. a, c, The midtemporal cortex of AD
cases showed numerous EAAT1/tau-positive neurons (arrows indicate
some labeled neurons). a, Labeling for EAAT1. c, Subsequent double
labeling with tau antibodies; tau was observed in the EAAT1-positive
cells only. b, d, The midtemporal cortex of control cases showed no or
extremely rare EAAT1/tau-positive cells (arrows). b, Immunostaining
with EAAT1. d, Double-labeling of EAAT1-positive cells with tau. Scale
bars, 20 m.
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cases that did not have Alzheimer-type pathology (i.e., controls,
cases with pure Lewy body disease, and a dementia case with
infarct pathology) confirmed that these changes in EAAT1 ex-
pression were specific to cases showing neurofibrillary pathology.
Previous studies have found no difference in EAAT1 protein
levels between AD and control cases (Li et al., 1997; Beckstrøm
et al., 1999), with a slightly lower, but not significant, EAAT1
immunoreactivity in the AD inferior temporal cortex (Beckstrøm
et al., 1999). Our study would suggest an increase in EAAT1
protein levels in the midtemporal cortex of dementia cases show-
ing Alzheimer-type pathology. This could be attributable to the
different area studied or to different treatment of the tissue. [One
of the previous studies used fresh, frozen tissue sections (Beck-
strøm et al., 1999) rather than fixed tissue.] Although one study
did show light labeling for EAAT1 in pyramidal cells, the authors
did not comment on the level of labeling for EAAT1 between AD
and control cases (Li et al., 1997).
Postmortem delay proteolysis of these proteins (EAAT1 and
EAAT2) has been shown to be fairly rapid in rat brain tissue, with
immunoreactivity being stable for the first 12 hr of storage at
room temperature and reducing significantly after that (Beck-
strøm et al., 1999). In our human cases, postmortem proteolysis
did not seem to be a problem, and we could detect strong
immunoreactivity up to at least 55 hr postmortem.
These observations, along with the finding that a few cells that
stained for EAAT1 did not stain for tau, whereas all tau-positive
cells were also EAAT1-positive, implicates abnormal glutamate
transporter expression in the pathology of AD. The expression of
a glutamate transporter not normally found in neurons could
imply that (1) abnormal EAAT1 expression precedes, and leads
to, tangle formation in affected neurons; (2) the expression of
EAAT1 is a mechanism to control or prevent excitotoxic damage
if increased concentrations of glutamate are present in the extra-
cellular space, and occurs either in addition to normal glial cell
function or to replace glial cell function if this is impaired; or (3)
the abnormal EAAT1 expression is a result of the pathology
already induced within the cell (e.g., by hyperphosphorylation of
tau or increased calcium concentrations). The observation that
some cells labeled for EAAT1 but not tau suggests that abnormal
EAAT1 expression precedes the tau labeling.
We conclude that glutamate transport is altered in dementia
cases showing Alzheimer-type pathology, with aberrant expres-
sion of EAAT1, and that these changes occur before, but are
related to, neurofibrillary pathology. These findings strongly im-
plicate glutamate-mediated toxicity as an important mechanism
involved in the neurodegeneration observed in AD.
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